SUMMARY -The behavior of CSF inflammatory pattern in patients with AIDS and/or toxoplasmosis of the CNS is studied in 176 patients, divided in three groups. In the first group, 96 patients with toxoplasmosis and AIDS are considered; in the second group, 50 patients with toxoplasmosis without AIDS; in the third group, 30 AIDS patients without toxoplasmosis nor any other opportunistic infection. It is possible to conclude that patients with toxoplasmosis associated to AIDS exhibit CSF inflammatory pattern similar to patients with neurotoxoplasmosis without AIDS, except in respect to gamma globulin rates for which a cumulative effect can be detected. 
The present investigation aims to analyze main CSF inflammatory phenomena in patients with neurotoxoplasmosis, comparing a group with AIDS to another group without detectable immunodeficiency.
MATERIAL, AND METHOD'S
This study includes 176 patients with clinical symptoms suggestive of CNS infectious disease, submitted to CSF analysis. CSF inflammatory characteristics were present in all patients. These patients were divided in three groups.
In the first group were considered 96 patients with AIDS and neurotoxoplasmosis, without evidence of another associated infection. In this group, 79 (85%) were male, with male: female rate 5.7:1.0. Age ranged from 2 to 58 years, with mean ± standard deviation --= 32.9 ± 9.41 years; median, 32.
The second group comprises 50' patients with neurotoxoplasmosis, without antibodies to HIV nor clinical manifestations suggestive of AIDS. In this group, 33 (66%) were male, with male: female proportion of 1.9:1.0. Age ranged from 1 day to 59 years; mean ± standard deviation 19.4 ± 17.55; median 13.
The third group includes 30 patients with CSF inflammatory characteristics associated to HIV antibodies in the CSF, without evidence of infection by Toxoplasma gondii nor any other opportunistic detectable agent. In this group, 25 (83%) were male, with male: female rate 4.9:1.0. Age ranged from 24 to 65 years; mean ± standard deviation -37.3 ± 10.99; median, 35.
CSF analysis was carried out in, all patients. It includes: classical examination (at least cell count and cytomorphologic profile, proteins and protemogram, glucose, chlorides, enzymes) ; bacteriologic, mycologic and myeobacteriologie exams (direct and cultures); bacterial antigens (Neisseria meningitidis A, B, C, Y, W 335 ; Hemophilus influenzae; Streptoceocus pneumoniae; Streptococcus b) and capsular antigens of Cryptococcus neoformans search; tests for detection of antibodies to syphilis, cysticercosis, schistosomyasis mansoni, Chagas disease, tuberculosis, histoplasmosis, paracoccidioidomycosis, candidiasis, aspergillosis; tests for antibodies to Cytomegalovirus, Varicella-zoster Herpes simplex and HIV.
In all patients were searched antibodies to Toxoplasma gondii in CSF: IgG antibodies by indirect immunofluorescence method and by passive hemagglutination test; IgM only by passive hemagglutination test.
CSF general inflammatory characteristics (cytology, proteins, gamma globulin) were considered for quantitative study. Hypotheses were analyzed by the Mann-Whitney U test (alpha = 0.10).
RESULTS
Results for cells, proteins and gamma globulins in the CSF are summarized in Table 1 . The quality of this modification seems to be determined more by Toxoplasma gondii infection than by HIV infection. In fact, CSF inflammatory characteristics from patients with toxoplasmosis associated to AIDS (group 1) and CSF from patients with neurotoxoplasmosis without AIDS (group 2) are similar in respect to cell count (p = 0.69) and proteins (p=0.84). However, gamma globulins rates are more elevated in patients with toxoplasmosis associated to AIDS (p = 0.0009); this may be explained by the basal high rates of gamma globulins present in patients with CNS involvement by AIDS.
In conclusion, patients with toxoplasmosis associated to AIDS exhibit CSF inflammatory profile similar to patients with neurotoxoplasmosis without AIDS, except in respect to gamma globulins rates; for these, a cumulative effect can be detected.
